Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OXiGENE OXGN

Healthcare Biotechnology
"OxiGene Inc is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It is currently developing two clinical stage investigational drugs, both VDAs- CA4P and OXi4503."

Recent & Breaking News (NDAQ:OXGN)

OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

GlobeNewswire October 7, 2014

OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society

GlobeNewswire October 6, 2014

OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors

GlobeNewswire September 17, 2014

OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9

GlobeNewswire August 26, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

OXiGENE Reports Second Quarter 2014 Financial Results

GlobeNewswire August 5, 2014

OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast

GlobeNewswire July 23, 2014

OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering

GlobeNewswire May 23, 2014

OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer

GlobeNewswire May 16, 2014

OXiGENE Reports First Quarter 2014 Financial Results

GlobeNewswire May 6, 2014

OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast

GlobeNewswire April 22, 2014

OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference

GlobeNewswire April 7, 2014

Celsius Holdings Inc.'s Stock Volume Falls amid Minimal News

Accesswire April 1, 2014

OXiGENE Announces Presentation of Three Preclinical Abstracts at 2014 AACR Conference

GlobeNewswire March 27, 2014

OXiGENE Reports Full Year 2013 Financial Results

GlobeNewswire March 18, 2014

UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer

GlobeNewswire March 11, 2014

OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer

GlobeNewswire March 11, 2014

OXiGENE Announces Updated Time for Presentation at the ROTH Conference

GlobeNewswire March 11, 2014

OXiGENE Announces Presentation at the ROTH Conference on March 11, 2014

GlobeNewswire March 7, 2014

OXiGENE Announces Full Year 2013 Earnings Conference Call and Webcast

GlobeNewswire March 4, 2014